Enochian Biosciences surges as FDA accepts request to review potential HIV cure

Lunai Bioworks

14/06/2021 13:22

** Shares of drug developer  ENOB.O  surge 146.03% to $10.85
premarket 
    ** U.S. FDA accepts co's pre-Investigational New Drug
request to treat HIV, based on results of a 54-year old HIV
patient who had failed to suppress the virus with antiviral
therapy  urn:newsml:reuters.com:*:nGNE1CctpD
    ** Co says viral control was achieved for 255 days with an
innovative treatment of Natural Killer (NK) and Gamma Delta
T-cells (GDT) collected from another person
    ** ENOB adds GDT cells, a small subset of immune cells that
can be infected with HIV, could be a key factor in controlling
the virus
    ** About 4.3 mln shares have traded premarket, ~3,353% of
their 30-DMA volume - Refinitiv data
    ** As of last close, stock up 49.5% YTD

 (Reporting by Devik Jain in Bengaluru)
 ((Devik.Jain@thomsonreuters.com; within U.S. +1 646 223 8780;
outside U.S. +91 80 6182 2062; ;))